Acute Renal Failure Clinical Trial
— DETECT-IP:Official title:
Reduction of Acute Renal Failure and/or Hyperkaliemia Adverse Drug Events in Older Inpatients by Incorporating Specific Rules Into a Computerized Support System and Dedicated Procedures: a Randomized Trial.
Current evidence shows that computerized decision support systems (CDSS) have shown to be insufficiently effective to prevent adverse drug reactions (ADRs) at large scale (e.g. whole hospital). Several barriers for successful implementation of CDSS have been identified: over-alerting, lack of specificity of rules, and physician interruption during prescription. The effectiveness of CDSS could be increased in two ways. Firstly, by creating rules that are more specific to a given adverse drug reaction: the current study focuses on acute renal failure and hyperkalemia (two serious and frequent ADR in older hospitalized patients). Secondly, by involving the pharmacist in the review of the alerts so that he/she can transmit, if deemed necessary, a pharmaceutical recommendation to the clinician. This procedure will reduce over-alerting and prevent task interruption. The hypothesis is that the use of specific rules created by a multidisciplinary team and implemented in a CDSS, combined with a strategy for managing and transmitting alerts, can reduce specific ADRs such as hyperkalemia and acute renal failure.
Status | Not yet recruiting |
Enrollment | 4920 |
Est. completion date | July 2024 |
Est. primary completion date | July 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 65 Years and older |
Eligibility | Inclusion Criteria: - Hospitalized for 3 days or more in an MCO (medicine surgery obstetrics) department participating in the study - Patient who gave oral consent to participate in the study - Socially insured patient Exclusion Criteria: - Patient discharged or died before D3 of hospitalization - Patient in palliative care or end of life on entry to the service - Person under legal protection (curatorship) - Lack of coverage by the social security system, Failure to obtain oral consent to participate in the study |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Lille | OméDIT (Observatory of Medicines, Medical Devices and Therapeutic Innovations, Regional Agency of Sante Nord Pas-de-Calais |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of adverse drug events such as acute renal failure and/or hyperkalemia in older hospitalized patients. | through study completion, an average of 20 days | ||
Secondary | Presence of an adverse event related to the intervention provided ("change of prescription", "discontinuation of drug") | through study completion, an average of 20 days | ||
Secondary | Therapeutic adaptations implemented in case of acute renal failure (ARF) or hyperkalemia upon hospital admission | Therapeutic changes within 72 hours of a CDSS alert for acute renal failure or hyperkalemia. Therapeutic changes include discontinuation of drug therapy, introduction of a new drug, dose reduction or change of drug | through study completion, an average of 15 days | |
Secondary | Relevance of CDSS alerts | Relevance of CDSS alerts is defined in a standard way. Each CDSS alert is evaluated by a clinical pharmacist according to their own expertise and data available in the EHR. If the alert was deemed not relevant, the clinical pharmacist did not perform any pharmaceutical intervention. The CDSS software register the classification of the alert as "not relevant". This approach was used the last 4 years in our hospital and as been published in an article published in the International Journal of Medical Informatics: Cuvelier E, Robert L, Musy E, Rousselière C, Marcilly R, Gautier S, Odou P, Beuscart JB, Décaudin B. The clinical pharmacist's role in enhancing the relevance of a clinical decision support system. Int J Med Inform. 2021 Nov;155:104568. doi: 10.1016/j.ijmedinf.2021.104568. Epub 2021 Sep 2. PMID: 34537687 | through study completion, an average of 20 days | |
Secondary | Number of pharmaceutical interventions accepted | When an alert is received by the pharmacist, it is analyzed and the pharmacist forwards a pharmaceutical intervention to the physician in charge of the patient to propose a modification of the treatment (dosage, dose, stop | through study completion, an average of 20 days | |
Secondary | Changes in ADEs (Adverse Drug Event) prevention/management work process induced by the introduction of alerts | Changes in the work system are identified through a comparison of its elements (tools, tasks, organization, interactions, work environment, professionals), before and after the introduction of alerts, using qualitative system engineering methods. | Through study completion, an average of 20 days | |
Secondary | Cost-effectiveness of the pharmaceutical intervention | Use medico-economic data such as time spent treating an alert, cost of treating an adverse drug reaction to estimate the cost-effectiveness of the intervention | through study completion, an average of 20 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01946113 -
Mineral-Homeostasis in Continuous Renal Replacement Therapy
|
N/A | |
Withdrawn |
NCT00993733 -
Assessing the Impact of Two Methods of Continuous Veno-venous Hemodiafiltration on Time Nursing Work in Intensive Care
|
N/A | |
Completed |
NCT01476995 -
Prognostic Indicators as Provided by the EPIC ClearView
|
N/A | |
Terminated |
NCT00978354 -
Furosemide in Early Acute Kidney Injury
|
Phase 2/Phase 3 | |
Completed |
NCT00120263 -
Trial of Plasma Exchange for Acute Renal Failure at the Onset of Myeloma
|
N/A | |
Completed |
NCT04799600 -
The Effect of the Severity of COVID-19 Disease on the Incidence of Acute Renal Failure in ICU
|
||
Recruiting |
NCT04334707 -
Kidney Precision Medicine Project
|
||
Completed |
NCT02858531 -
Predictive Tracking of Patient Flow in the Emergency Services During the Virus Winter Epidemics
|
||
Recruiting |
NCT05282732 -
Retrospective Analysis of Performance and Treatment Data Collected for Genius SleddFlux Filter, Ultraflux AV 600 S Filter & Genius 90 Concentrates in Haemodialysis Patients
|
||
Completed |
NCT01467466 -
Prevention of Serious Adverse Events Following Angiography
|
Phase 3 | |
Completed |
NCT01979042 -
Urinary Markers for Unilateral Kidney Obstruction
|
N/A | |
Completed |
NCT01280617 -
Low Dose Thymoglobin in Renal Transplant Patients
|
N/A | |
Completed |
NCT00780351 -
Dosing Vancomycin in Patients on Sustained Low Efficiency Daily Hemodiafiltration (SLEDD-f)
|
N/A | |
Completed |
NCT00971971 -
Prevention of Intradialytic Hypotension in Acute Kidney Injury Patients
|
N/A | |
Completed |
NCT00076219 -
Acute Renal Failure Trial Network (ATN) Study
|
Phase 3 | |
Recruiting |
NCT04599569 -
Influence of Renal Replacement TherApy on Indirect Calorimetry
|
||
Completed |
NCT03727204 -
Acute Kidney Injury After Cardiac Surgery: Novel Ultrasound Techniques for Prediction of Acute Kidney Injury
|
||
Completed |
NCT06005896 -
A Clinical Model for Dialysis Discontinuation in AKI
|
||
Completed |
NCT03004950 -
Biomarker Effectiveness Analysis in Contrast Nephropathy (BEACON)
|
||
Completed |
NCT03627884 -
Outcomes of the Use of Sodium Bicarbonate (8.4%) Solution as a Catheter Lock Solution to Prevent Hemodialysis Catheter Loss Due to Lumen Clot Formation
|
Phase 4 |